Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment
Status:
Completed
Trial end date:
2018-02-05
Target enrollment:
Participant gender:
Summary
Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based
effective and safe treatment option. This study compares the effects of low-dose testosterone
and aromatase inhibitor letrozole on pubertal progression. The hypothesis is that, in boys
CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo) induces faster
biochemical and clinical progression of puberty as compared to low-dose intramuscular
testosterone Rx (~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select watchful
waiting instead of medication will provide background data on the natural progression of
CDGP, and their data will not be used in primary statistical comparisons.